Biogen Shares Plummet: Future Growth at Risk?

Biogen Shares Experience Significant 5% Drop in Pre-market Trading

Biogen shares are experiencing a significant 5% drop in premarket trading on Tuesday following the company’s disappointing earnings report for the latest quarter. The renowned biotechnology firm recorded fourth-quarter earnings of $2.95 per share, falling short of analysts’ expectations by $0.23. Additionally, the company’s quarterly revenue stood at $2.4 billion, significantly lower than the consensus estimate of $2.47 billion.